Breakingviews: Mylan failure fallout
0
The drugmaker's $26 bln hostile bid for rival Perrigo collapsed after Mylan snubbed an earlier takeover offer from Teva. Rob Cyran and Jeffrey Goldfarb discuss what happens next.